BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 169 filers reported holding BRIDGEBIO PHARMA INC in Q4 2020. The put-call ratio across all filers is 0.33 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,701,841 | +49.1% | 64,537 | -2.8% | 1.04% | +57.9% |
| Q2 2023 | $1,141,444 | -0.0% | 66,363 | -3.6% | 0.66% | -7.8% |
| Q1 2023 | $1,141,749 | +119.6% | 68,863 | +0.9% | 0.71% | +108.2% |
| Q4 2022 | $520,012 | -27.3% | 68,243 | -5.2% | 0.34% | -31.4% |
| Q3 2022 | $715,000 | +9.5% | 71,966 | +0.1% | 0.50% | +14.4% |
| Q2 2022 | $653,000 | -10.4% | 71,884 | +0.1% | 0.44% | +10.4% |
| Q1 2022 | $729,000 | -37.6% | 71,829 | +2.5% | 0.40% | -31.5% |
| Q4 2021 | $1,169,000 | -1.5% | 70,059 | +176.7% | 0.58% | -6.0% |
| Q3 2021 | $1,187,000 | -23.2% | 25,319 | -0.1% | 0.62% | -21.2% |
| Q2 2021 | $1,545,000 | -3.0% | 25,345 | -1.9% | 0.78% | -7.4% |
| Q1 2021 | $1,592,000 | -12.8% | 25,839 | +0.6% | 0.84% | -21.2% |
| Q4 2020 | $1,826,000 | +85.2% | 25,681 | -2.3% | 1.07% | +51.6% |
| Q3 2020 | $986,000 | +14.8% | 26,288 | -0.2% | 0.70% | +5.4% |
| Q2 2020 | $859,000 | +32.2% | 26,334 | +17.5% | 0.67% | +2.8% |
| Q1 2020 | $650,000 | – | 22,410 | – | 0.65% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $55,099,000 | 39.31% |
| M28 Capital Management LP | 466,200 | $4,233,000 | 4.74% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $282,034,000 | 3.75% |
| Octagon Capital Advisors LP | 933,743 | $8,478,000 | 2.26% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $241,719,000 | 1.11% |
| HHLR ADVISORS, LTD. | 5,362,014 | $48,687,000 | 1.04% |
| Cormorant Asset Management, LP | 1,469,179 | $13,340,000 | 1.01% |
| Knott David M Jr | 213,206 | $1,936,000 | 0.81% |
| Fernwood Investment Management, LLC | 183,900 | $1,670,000 | 0.72% |
| HighVista Strategies LLC | 105,942 | $962,000 | 0.58% |